Levilactobacillus brevis CD2 as a multifaceted probiotic to preserve oral health: results of a double-blind, randomized, placebo-controlled trial in healthy adults.

J Transl Med · 2025 · PMC11776208 · PMID 39875908

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

brevis CD2 treatment resulted in a highly significant reduction in BoP score compared to baseline ( p < 0.0001 ).

also in 132,142 other papers

did not reach statistical significanceno p-value reported

Regarding the impact of the probiotic treatment on salivary glucose levels, although the results did not reach statistical significance, a downward trend was observed following the intake of L. brevis CD2 compared to baseline.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.